FCM
NBIX icon

Flinton Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Flinton Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$760K Buy
8,432
+208
+3% +$19.4K 0.02% 354
2019
Q2 		$694K Buy
8,224
+4,832
+142% +$397K 0.02% 397
2019
Q1 		$299K Buy
3,392
+800
+31% +$66.9K 0.01% 594
2018
Q4 		$185K Buy
+2,592
New +$248K 0.01% 668

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flinton Capital Management's NBIX Position: Q3 2019 in Review

Flinton Capital Management increased its Neurocrine Biosciences (NBIX) stake by 2.5% in Q3 2019, buying an estimated $19.4K and bringing the position to 8,432 shares worth $760K. The position accounts for 0.02% of the portfolio, ranked #354.

Flinton Capital Management first reported a position in NBIX in Q4 2018 and has held it in 4 quarters since. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Flinton Capital Management held 8,432 shares of Neurocrine Biosciences worth $760K as of Q3 2019.
  • Flinton Capital Management bought 208 Neurocrine Biosciences shares in Q3 2019, an estimated $19.4K.
  • Neurocrine Biosciences made up 0.02% of Flinton Capital Management's portfolio in Q3 2019, its #354 holding.
  • Flinton Capital Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 4 quarters since.
  • 332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.